Latest AbbVie News & Updates
See the latest news and media coverage for AbbVie. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biopharmaceutical company
abbvie.com- Headquarters
- North Chicago, United States
- Company type
- Public company
- Number of employees
- 60,000+
Latest news about AbbVie
Company announcements
-
AbbVie reports first-quarter 2026 financial results
Net revenues reach $15.002 billion, up 12.4%. Raises full-year adjusted EPS guidance to $14.08-$14.28. Key portfolios show strong growth in immunology and neuroscience.
-
AbbVie submits FDA application for RINVOQ in severe alopecia areata
Submission supported by Phase 3 UP-AA trials showing substantial scalp hair regrowth at week 24 and beyond.
-
AbbVie submits FDA application for SKYRIZI subcutaneous induction
The submission is supported by Phase 3 AFFIRM study data for adults with moderately to severely active Crohn's disease. Approval would offer SC induction option alongside IV.
-
AbbVie receives FDA CRL for TrenibotE BLA
The FDA requests manufacturing information without safety or efficacy issues or new studies. AbbVie plans a prompt response. Reviews continue elsewhere.
Media coverage
-
AbbVie (ABBV) Reports Q1 Revenue Growth Despite Earnings Miss
On May 02, 2026, AbbVie (ABBV) announced its Q1 earnings, revealing a revenue of approximately $15 billion, which marks a 12% increase year-over-year. However...
-
AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
National competition, in collaboration with adMare BioInnovations, demonstrates AbbVie's commitment to a thriving biotech ecosystem in Quebec.Award provides RIME Therapeutics with a year of laboratory...
-
AbbVie Gains Right to Buy Pan-KRAS Inhibitor Developer Kestrel for up to $1.45B
Kestrel has dosed the first patient in its Phase I trial evaluating KST-6051 in patients with advanced or metastatic solid tumors with KRAS mutations.
-
AbbVie's patent on immunology therapy rejected
In good news for patients, Indian Patent Office has refused a patent on MNC firm AbbVie's blockbuster immunology therapy Rinvoq, paving the.
Track AbbVie and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
AbbVie competitors & trending companies
Browse news for competitors to AbbVie and other trending companies.